Pre-exposure prophylaxis (PrEP) is a promising strategy to break COVID-19 transmission. Although hydroxychloroquine was evaluated for treatment and post-exposure prophylaxis, it is not evaluated for COVID-19 PrEP yet. The aim of this study was to evaluate the efficacy and safety of PrEP with hydroxychloroquine against placebo in healthcare workers at high risk of SARS-CoV-2 infection during an epidemic period.
Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: a double-blind, placebo-controlled randomized clinical trial / Grau-Pujol, B., Camprubí-Ferrer, D., Marti-Soler, H., Fernández-Pardos, M., Carreras-Abad, C., Andrés, M.V., Ferrer, E., Muelas-Fernandez, M., Jullien, S., Barilaro, G., Ajanovic, S., Vera, I., Moreno, L., Gonzalez-Redondo, E., Cortes-Serra, N., Roldán, M., Arcos, A.A., Mur, I., Domingo, P., Garcia, F., et al.. - In: TRIALS. - ISSN 1745-6215. - 22:1(2021). [10.1186/s13063-021-05758-9]
Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: a double-blind, placebo-controlled randomized clinical trial
Barilaro, GiuseppeInvestigation
;
2021
Abstract
Pre-exposure prophylaxis (PrEP) is a promising strategy to break COVID-19 transmission. Although hydroxychloroquine was evaluated for treatment and post-exposure prophylaxis, it is not evaluated for COVID-19 PrEP yet. The aim of this study was to evaluate the efficacy and safety of PrEP with hydroxychloroquine against placebo in healthcare workers at high risk of SARS-CoV-2 infection during an epidemic period.| File | Dimensione | Formato | |
|---|---|---|---|
|
Grau-pujol_Hydroxychloroquine_2021.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
800.23 kB
Formato
Adobe PDF
|
800.23 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
